TNF and SAPHO syndrome: Tumor necrosis factor inhibitors (TNF inhibitors), such as infliximab, adalimumab, and etanercept, are biologic DMARDs that reduce inflammation and bone damage by inhibiting TNF, making them the preferred treatment for many rheumatic diseases, including SAPHO syndrome.